Comparison of Pamidronate With Zoledronic Acid for Transplant Related Bone Loss Prevention

• Status: Completed
• Trial end date: 2005-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this trial is to see whether zoledronic acid is better than pamidronate to treat low bone density in heart and lung transplant patients.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bayside Health
• Collaborator: Novartis
• Treatments: Diphosphonates; Pamidronate; Zoledronic Acid

Criteria

Inclusion Criteria:

• reduced bone density as indicated by a bone density T score <-1.in either the lumbar spine or femoral neck

• have undergone or are on the waiting list for heart or lung transplantation

• are receiving adequate calcium and vitamin D therapy

• have provided written informed consent prior to participation in the trial

Exclusion Criteria:

• untreated hypogonadism, hypothyroidism or hyperthyroidism

• acute or major organ rejection or intercurrent illness

• pregnancy or breastfeeding